John Slump, President/Co-Founder, is a serial medtech entrepreneur with a proven track record as a founder and operating executive with three exits totaling over $1B of M&A transaction value. Mr. Slump was Co-Founder of Farapulse with Atraverse CTSO Dr. Steven Mickelsen, who pioneered the first pulsed field ablation (PFA) devices for treatment of atrial fibrillation (AF).  Farapulse raised over $100M and was acquired for up to $800M by Boston Scientific (NYSE: BSX). Mr. Slump was previously the CFO & Co-Founder of Attune Medical, an esophageal temperature management device company that raised over $25M and grew to over $20M in annual sales, leading to the acquisition by Haemonetics (NYSE: HAE) for $160M. Mr. Slump was also the CFO of Surgical Innovation Associates (SIA), manufacturer of an implantable device for breast cancer patients, which raised over $20M and grew $0-10M in annual sales, culminating in a strategic  acquisition by Integra  LifeSciences (NASDAQ: IART) for up to $140M. John holds a B.B.A in Finance from University of Iowa. Mr. Slump is concurrently CFO of Volta Medical, a health tech company developing AI software technology designed to assist cardiac EP’s in AF ablation procedures. 

Dr. Steven Micklesen, Chief Translational Science Officer (CTSO)/Co-Founder, is a recognized expert in cardiac ablation and pioneer in PFA technology. In 2012, he co-founded Farapulse, a company largely credited with shifting paradigms in the way physicians now treat AF, the world's most common clinical cardiac arrhythmia. Farapulse was the first PFA system approved for the European market. More recently, Dr. Mickelsen served as CTSO for Acutus Medical, a publicly traded EP device company. After receiving his medical degree from the University of New Mexico School of Medicine, Dr. Mickelsen was a Research Scholar at Howard Hughes Medical Institute, as well as a Resident Physician at Mayo Clinic and completed his EP fellowship at the University of Iowa. Dr. Mickelsen is also a practicing EP physician at Scripps Clinic in La Jolla, California. Dr. Mickelsen is concurrently CEO of Field Medical, a PFA therapy device for Ventricular Tachycardia (VT) ablation.

Eric Sauter, COO/Co-Founder, brings over 10 years of medical device development experience in the cardiac EP field. Eric started his career as employee #1 of Farapulse and has since held R&D roles at Abbott, Teleflex, Access Point Technologies, and Freudenberg.  Mr. Sauter has significant experience in developing energy-based therapies in the cardiac EP space. He has participated in “bench to bedside” hands-on support for two First-In-Human clinical studies, Farapulse IMPACT and Acutus PFA-CE, advancing technologies from the early concept phase through preclinical evaluations and successful clinical use. Mr. Sauter has extensive experience in cleanroom manufacturing, operations, device controls, quality management, and design assurance testing. Mr. Sauter holds a B.S.E. in Chemical Engineering from University of Iowa.

Jay Kelley, SVP Marketing, brings over 20 years of medical device R&D and commercialization experience, primarily focused in the cardiac EP field. He has held a variety of leadership roles at Medtronic and J&J (Biosense Webster) as well as several startups, with functional expertise ranging from Advanced R&D to Marketing, Clinical Affairs, and Training/Education. Jay’s start-up experience includes Ablation Frontiers (acquired by Medtronic for up to $225 million) and Filmetrics (acquired by KLA). He holds a B.S. in Bioengineering from UCSD, M.S. in Biomedical Engineering from Keck Graduate Institute, and an M.B.A. from Drucker School of Management at Claremont Graduate University.

TJ Strang, VP Engineering, is an engineering leader who brings over 20 years of product development experience in the medical device industry, primarily in the device-based treatment of cardiac arrythmias. He led product development for implantable cardiac leads for St. Jude Medical/Abbott, and recently led product development for cardiac mapping and ablation catheters at Acutus Medical. In addition to performing technical due diligence at St. Jude Medical for various acquisition targets, his direct start-up experience includes   Bacchus Vascular   (acquired by Covidien).   Mr. Strang  holds a B.S. in  Chemical Engineering from Brigham Young University and an M.B.A. from UCLA Anderson School of Business.

Charles Yang, SVP QA/RA, is a seasoned executive with over 20 years of medical device regulatory and quality experience. He’s helped several cardiovascular companies secure regulatory approvals in the U.S., Europe, Japan, Canada, Australia, and other countries and has successfully supported FDA and other regulatory body audits. He was previously Co-founder of RC Medical, an incubator which spun out multiple companies. He was also a founder of an OEM manufacturer of medical devices. Previously, Charles worked with Blockade Medical (acquired by Balt in 2016), Ablation Frontiers (acquired by Medtronic for up to $225 million), and Edwards Lifesciences. Charles received a B.S. in Bioengineering at UCSD.